12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bavituximab: Additional Phase II data

Additional data from an open-label, international Phase II trial in 83 evaluable patients with previously untreated stage IIIb/IV NSCLC showed that once-weekly 3 mg/kg bavituximab plus carboplatin and paclitaxel led an estimated median PFS of 5.8 months vs. 4.6 months for carboplatin and paclitaxel alone. Bavituximab plus chemotherapy led...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >